0001640334-23-001155.txt : 20230629 0001640334-23-001155.hdr.sgml : 20230629 20230629162455 ACCESSION NUMBER: 0001640334-23-001155 CONFORMED SUBMISSION TYPE: 6-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230628 FILED AS OF DATE: 20230629 DATE AS OF CHANGE: 20230629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NYMOX PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001018735 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-12033 FILM NUMBER: 231057736 BUSINESS ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 BUSINESS PHONE: 1-800-936-9669 MAIL ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 6-K/A 1 nymox_6ka.htm FORM 6-K/A nymox_6ka.htm

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K/A

 

 (Amendment No. 1)

  

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

  

For the Month of June 2023

 

Commission File Number: 001-12033

 

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

 

Bay & Deveaux Streets, Nassau, The Bahamas 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

  

EXPLANATORY NOTE

 

This Current Report on Form 6-K/A of Nymox Pharmaceutical Corporation (the “Company”) amends the Company’s Current Report on Form 6-K as filed with the Securities and Exchange Commission on June 27, 2023 (the “Original Filing”) to correct a typographical error referring to the Company’s termination of employment of Mr. Christopher R. Riley as the Company’s Chief Financial Officer and of Mr. Randall J. Lanham as the Company’s Chief Operating Officer on June 19, 2023. The correct date of such terminations is June 17, 2023.

 

Except as described herein, no other changes have been made to the Original Filing.

 

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 29, 2023

 

 

NYMOX PHARMACEUTICAL CORPORATION
       
By:

/s/ Paul Averback

 

Name:

Paul Averback

  
 

Title:

President and Chief Executive Officer

  

 

 

3